fda warning letters compounded semaglutide september 2025 U.S. sends drug advertising to Lilly, Novo, Hims FDA Issues Warning Letters to

A comprehensive meta-analysis of T2DM and the risks of developing cancer and mortality showed that the presence of diabetes was associated with a 10% increase in the relative risk of developing cancer [4]

First review of the potential renoprotective effects and mechanisms of GLP-1R agonists and DPP-4 inhibitors in preclinical studies and in early clinical studies involving patients with diabetes

Blood pressure readings demonstrating hypertension

Weight loss is not guaranteed and is influenced by many factors, including diet, exercise, and individual biology." Results described by the brand or individual customer accounts are not representative of typical or guaranteed outcomes

GLP-1s are powerful hormones

Simultaneous fat loss may be occurring, but water weight masks it on the scale